ReviewEuropean cardiology2026
Revascularisation in Patients with Cancer: A Review.
Review in European cardiology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Current Perspectives in Cardio-oncology: Insights from Global Experts.European cardiology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The emerging field of cardio-oncology has grown considerably over the past two decades. While the issue of myocardial cardiotoxicity has received the most attention, it is now recognised that cardio-oncology encompasses the full spectrum of cardiovascular disease, which includes invasive therapy as part of management. Historically, these were seldom considered in cancer patients, due to their perceived poor prognosis and high risk of complications. However, advances in diagnosis and therapy have improved the prognosis and lifespan of patients with cancer, rendering a generally conservative approach no longer appropriate. Despite this, their management remains challenging, perhaps more so than in any other subset of patients. As patients with cancer become increasingly more common in catheterisation laboratories, we review the issue of revascularisation in this patient subset to address three major issues: available evidence, appropriateness of revascularisation, and specific factors to consider when performing revascularisation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.